Clinical and pharmacological group: & nbsp

Prostaglandins, thromboxanes, leukotrienes and their antagonists

Included in the formulation
  • BIMOPTIC ROMFARM
    drops d / eye 
  • Latisse
    drops locally 
    Allergen, Inc.     USA
  • АТХ:

    S.01.E.E.03   Bimatoprost

    Pharmacodynamics:

    Synthetic proteamide, which is structurally related to PGF2α, not acting through known prostaglandin receptors. Has a selective hypotensive effect on intraocular pressure, enhancing the outflow of intraocular fluid through the trabecular network.

    Has no significant effect on blood pressure and heart rate. Stimulates and lengthens the growth phase of the hair follicles of the eyelashes.

    Pharmacokinetics:

    After instillation in the conjunctival sac is absorbed into the systemic blood flow weakly, the maximum concentration in the blood plasma is reached after 10 minutes. The connection with plasma proteins is 88%.

    Therapeutic effect develops after 4 hours after instillation, reaches a maximum in 8-12 hours and lasts for 24 hours. Metabolism in the vascular bed.

    The half-life is 45 minutes. Elimination by the kidneys.

    Indications:

    It is used for the treatment and prevention of open-angle glaucoma. Used to increase the number of eyelashes with gipotrihoze eyelids.

    VII.H00-H06.H02   Other diseases of eyelids

    VII.H40-H42.H40.1   Primary open angle glaucoma

    VII.H40-H42.H40.0   Suspicion of glaucoma

    Contraindications:

    Age to 18 years, pregnancy and lactation, individual intolerance.

    Carefully:

    Afakia, pseudophakia, artifacty, rupture of the posterior capsule of the lens, inflammatory diseases of the eyelids, hypersensitivity.

    Pregnancy and lactation:

    Recommendations for FDA - Category C. Contraindicated in pregnancy and lactation.

    Dosing and Administration:

    Conjunctival, local.

    Side effects:

    Itching, burning of the conjunctiva, photophobia, impaired vision. Rarely - enopthalmus, hyperpigmentation of the iris, hirsutism.

    Allergic reactions.

    Overdose:

    Cases of overdose are not described.

    Treatment is symptomatic.

    Interaction:

    Clinically significant interactions are not described.

    Special instructions:

    When wearing soft contact lenses, their discoloration occurs due to interaction with benzalkonium chloride, which is contained in the preparation. It is recommended to remove the lens before use. Installation of lenses is possible not earlier than 15 minutes.

    When taking the drug is not recommended driving and working with moving machinery.

    Instructions
    Up